NNVC ▼ -3.8% - NanoViricides, Inc.
$NNVC - Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
13-OCT-2026 08:45 AM ET
Share this post
More filings for $NNVC
NNVC ▲ +1.4% - NanoViricides, Inc.Oct 6, 2026NNVC ▼ -0.8% - NanoViricides, Inc.Oct 5, 2026NNVC ▲ +4.0% - NanoViricides, Inc.Sep 29, 2026NNVC ▼ -2.1% - NanoViricides, Inc.Sep 28, 2026NNVC ▲ +5.2% - NanoViricides, Inc.Sep 23, 2026NNVC ▼ -0.9% - NanoViricides, Inc.Sep 8, 2026
View full $NNVC filing history →💬 Comments
Loading comments…
Leave a comment